• Neoadjuvant 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy is safe for neoadjuvant treatment for patients with localized human epidermal growth receptor 2-positive esophagogastric adenocarcinoma.
intravenously [IV] , days 1, 15, and 29), and lapatinib (six patients, 1,000 mg p.o., days 1-42; six patients, 750 mg p.o., days 1-42) plus radiation (1.8 Gy/day Monday through Friday for 50.4 Gy total). Following restaging, eligible patients underwent definitive resection, and pathologic response to neoadjuvant therapy was assessed. Planned enrollment was 42 patients. The primary endpoint was the pathologic complete response (pCR) rate. Results. Twelve patients (median age 64 years; 67% male) received a median of 5.6 weeks of treatment (range: 1.1-8.4). The pCR rate was 8%; four of the 12 patients underwent tumor resection and one patient had a pCR, with pathologic partial response in the remaining three. The most common lapatinibrelated adverse events included (all grades) nausea (67%) and diarrhea (58%), although these were all grade 1 or 2. Enrollment was halted due to low accrual. Conclusion. The treatment regimen was determined to be safe. The study was terminated early due to low accrual. The Oncologist 2017;22:1152-e98
DISCUSSION
Based on the potential efficacy of lapatinib in HER2 gastric tumors, this multi-institutional phase II trial was designed to assess lapatinib, 5-FU, and oxaliplatin in combination with radiation therapy for the neoadjuvant treatment of localized esophagogastric cancers in patients with no prior therapy for the disease. It was hypothesized that the pCR primary endpoint would be increased from 30%-50% in a study population of 30 patients. Twelve patients (median age 64 years; 67% male, 58% moderately differentiated, 83% esophageal, 100% HER2-positive) received a median of 5.6 weeks of treatment (range: 1.1-8.4). Four patients underwent tumor resection, and one of the four patients (25%) had a pCR. However, the number of patients evaluated here was too low to make an accurate comparison with other studies. Response Evaluation Criteria in Solid Tumors response assessment was performed for three patients, of whom two (67%) had at least a partial response. The most common lapatinib-related adverse events included nausea (67%) and diarrhea (58%). Enrollment was halted due to low accrual. Only 12 patients were accrued from February 2013 to December 2014, due partly to the low number of patients with HER2-positive gastroesophageal junction tumors. Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy. Neoadjuvant chemoradiation therapy for patients with localized esophagogastric cancers has been the subject of much discussion and controversy, with conflicting results compared with surgery alone seen in previous randomized clinical trials [1] [2] [3] . Pathologic complete response (pCR) rates after neoadjuvant chemoradiation therapy are in the 25% range [1] [2] [3] .
Approximately 22% of patients with gastric or gastroesophageal junction (GEJ) adenocarcinomas have tumors that are human epidermal growth factor receptor 2 (HER2)-positive [4] . The ToGA trial found that patients with HER2-positive gastric/ GEJ adenocarcinomas had a significant improvement in overall survival (11.1 months to 13.8 months) when trastuzumab was added to the chemotherapy. Response rate and progressionfree survival were improved (47% vs. 35% and 6.7 months vs. 5.5 months, respectively) [5] .
Lapatinib is a tyrosine kinase inhibitor of EGFR and HER2. It is U.S. Food and Drug Administration approved in combination with capecitabine for first-line treatment of HER2-positive advanced or metastatic breast cancer. In vivo, lapatinib has shown antitumor activity in gastric cancer cell lines when combined with 5-fluorouracil (5-FU) paclitaxel [6, 7] . A recent phase III trial to assess potential benefit of lapatinib in combination with chemotherapy for the firstline treatment of HER2-positive metastatic gastric cancer showed that while overall survival was not improved with the addition of lapatinib, the response rate was significantly higher in the lapatinib arm [8] . Similarly, results of the TyTAN trial of paclitaxel with or without lapatinib as treatment for Asian patients with HER2-positive gastric cancer did not show improvement in overall survival [9] . Based on the potential efficacy of lapatinib in HER2 gastric tumors, we designed a multi-institutional phase II trial of lapatinib, 5-FU, and oxaliplatin in combination with radiation therapy for the neoadjuvant treatment of localized esophagogastric cancers in patients with no prior therapy for the disease. It was hypothesized that the pCR primary endpoint would be increased from 30%-50% in a study population of 30 patients. Twelve patients (median age 64 years; 67% male, 58% moderately differentiated, 83% esophageal, 100% HER2-positive) received a median of 5.6 weeks of treatment (range: 1.1-8.4). Four patients underwent tumor resection and one of the four patients (25%) had a pCR, which was similar to the pCR rates of previously reported studies [1] [2] [3] . However, the number of patients evaluated in the present study was too low to make an accurate comparison with other studies. Response Evaluation Criteria in Solid Tumors response assessment was performed for three patients, of which two (67%) had at least a partial response. The most common lapatinib-related adverse events included nausea (67%) and diarrhea (58%).
Enrollment was halted due to low accrual. Only 12 patients were accrued from February 2013 to December 2014, due partly to the low number of patients with HER2-positive gastroesophageal junction tumors. Evaluation of this drug combination in a larger patient pool would allow for more accurate analysis of its efficacy. 
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